ProlivRx System
Neurolief , Ltd. · Decision date Dec 31, 2025
What did the FDA approve?
FDA records P250010 as an original PMA application. The recorded decision is approval, dated Dec 31, 2025.
FDA approval order statement
The ProlivRx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Dec 31, 2025
Regulatory record facts
- Identifier
- P250010
- Regulatory pathway
- Premarket approval application
- Applicant
- Neurolief , Ltd.
- Product code
- JXK
- Decision code
- APPR
- Decision date
- Dec 31, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cranial electrotherapy stimulator to treat depression.
- Applicant
- Neurolief , Ltd.
- Product code
- JXK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250010 received
Application receipt date recorded by FDA.
P250010 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250010. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code JXK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Flow FL-100P230024/S001 | Flow Neuroscience AB | PMA supplement | Jul 14, 2026 | FDA |
Flow FL-100P230024 | Flow Neuroscience AB | PMA approval | Dec 8, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neurolief , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 12 Giborei Israel St., Netanya, 4250412
Sources and methodology
- Original FDA record: P250010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
